Skip to content

Effects of Esketamine at Subanesthetic Dose on Emergence Delirium in Preschool Children Undergoing Ambulatory Laparoscopic Surgery

Effects of Esketamine at Subanesthetic Dose on Emergence Delirium in Preschool Children Undergoing Ambulatory Laparoscopic Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06789185
Enrollment
96
Registered
2025-01-23
Start date
2025-02-07
Completion date
2025-05-16
Last updated
2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal Hernia

Brief summary

Emergence delirium (ED) is a manifestation of acute postoperative brain dysfunction that occurs with a relatively high frequency after pediatric anesthesia. The incidence varies depending on the diagnostic criteria used and the combination of administered anesthetic drugs. The goal of this clinical trial is to investigate whether a subanesthetic dose of esketamine can reduce incidence of ED.

Interventions

DRUG0.1mg/kg esketamine

Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery

DRUG0.2mg/kg esketamine

Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery

DRUG0.1ml/kg normal saline

Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery

Sponsors

Qiu jinpeng
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
24 Months to 71 Months
Healthy volunteers
No

Inclusion criteria

1. laparoscopic inguinal hernia repair under general anesthesia 2. aged 24\ 71 months 3. American Society of Anesthesiologists Physical Status I or II 4. body mass index for age between the 5th and 85th percentiles

Exclusion criteria

1. allergy to esketamine 2. abnormal liver or kidney function 3. glaucoma or neurological disorders 4. cardiovascular or endocrine dysfunction 5. asthma or respiratory infection in the last 2 weeks 6. developmental delay

Design outcomes

Primary

MeasureTime frameDescription
The incidence of emergence deliriumWithin up to 30 minutes after emergence from anesthesiaThe pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score. Pediatric anesthesia emergence delirium scores ≥10 at any time indicates presence of emergence delirium.

Secondary

MeasureTime frameDescription
emergence from anesthesia timeWithin up to 30 minutes after operationThe time from the cessation of sevoflurane to the point when the child would respond to sound stimuli or open their eyes.
The incidence of postoperative painWithin up to 30 minutes after operationThe FLACC scale consists of five items. Each item is scored 0-2 yielding a total between 0 and 10. The degree of pain increased directly with the total score. FLACC scores 4 or greater indicates presence of emergence delirium.
Recovery timeWithin up to 50 minutes after operationThe time from the cessation of sevoflurane to the point when the child was awakened and responded readily to their name spoken in a normal tone of voice.
Tracheal catheter extubation timeWithin up to 30 minutes after operationThe time from the cessation of sevoflurane to the point when the tracheal catheter would be remove.
Blood pressureIntraoperative and up to postoperative 20 minutesBlood pressure of children were measured at 0min, 5min, 10min and 20min after injection of study drug or normal saline.
heart rateIntraoperative and up to postoperative 20 minutesheart rate of children were measured at 0min, 5min, 10min and 20min after injection of study drug or normal saline.
The incidence of adverse effects24 hours after surgery.Postoperative nausea, vomiting, salivation, bradycardia, hypotension, and respiratory depression within 24 hours after surgery.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026